Thrombosis  /  Innovative Medical Research

Each year around 75,000 Americans are diagnosed with atrial fibrillation (AFib), 900,000 experience a venous thromboembolism event (VTE), and 800,000 have a stroke. The burden for those who survive is enormous and the cost of care a major expense for individuals and the nation. Fortunately research advances are offering significant hope. A number of investigative anticoagulants have the potential to reduce strokes in AFib patients while also reducing the risk of bleeds; clot-dissolving agents are proving to lessen the effects of strokes; and the same drugs in the pipeline for AFib could prevent VTE after major orthopedic surgery.

28 Matching Facts

Search matching Facts:
No results to display
    • Savings associated with t-PA treatment for ischemic stroke patients
      A $600 net savings is associated with each ischemic stroke patient treated with t-PA. In 2005, only 2% of all ischemic stroke patients received t-PA. If that percentage was increased…  
    • Stroke prevention through optimal anticoagulation
      If half of atrial fibrillation patients who currently receive warfarin in a routine care setting had their anti-coagulation optimized, around 9,000 strokes and more than 29,000 bleeds would be prevented.  
    • Effect of optimal anticoagulation
      If 50% of atrial fibrillation patients who currently receive warfarin in routine medical care were optimally anticoagulated, 9,852 emboli would be prevented and $1.3 billion would be saved each year.  
    • Effects of optimal anticoagulation among AFib patients
      If 50% of individuals with atrial fibrillation who do not receive prophylaxis were optimally anti-coagulated, 19,380 emboli would be prevented and $1.1 billion would be saved each year.  
    • Cost-savings associated with optimal anticoagulation in AFib patients
      If half of all atrial fibrillation patients receiving suboptimal or no anticoagulation instead received optimal anticoagulation, 28,000 strokes could be prevented each year at a savings of around $2.5 billion in direct…  
    • Effectiveness of treating ischemic strokert-PA within 3 hours of symptom onset
      A study of the  victims with effectiveness of treating ischemic strokert-PA within 3 hours of symptom onset showed a decrease in rehabilitation costs of $1.4 million and nursing home costs of…  
    • t-PA cost savings
      The total annual benefit to society from t-PA use in the United States is around $363 million—$60 million in direct cost savings to society plus an additional 7,510 QALYs. This means…  
    • Per-patient annual cost of treating stroke in atrial fibrillation patients
      The per-patient annual cost of treating stroke in atrial fibrillation patients was found to be $1,485 in a wellcontrolled anti-coagulation clinic, $3,710 for those receiving warfarin in routine medical care,…  
    • Cost of warfarin therapy for AFib patients
      In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.  
    • Cost-savings associated with Warfarin use in AFib patients
      Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
    • AFib practice guidelines reduce direct health care costs
      The use of practice guidelines in atrial fibrillation (AF) patients significantly decreased hospitalization and resource utilization—with an average decrease in 30-day total direct health care costs of around $1,400 per patient.  
    • Effectiveness of an oral pharmacologic agent in preventing venous thrombosis
      An oral pharmacologic agent has been demonstrated to be at least as effective as an injectable anticoagulant in the prevention of venous thrombosis following hip replacement.  
    • Direct thrombin inhibitor reduced relative risk of venous thromboembolism
      An investigational direct thrombin inhibitor reduced relative risk of venous thromboembolism after total hip replacement surgery by 65.7%—compared to a currently available treatment.  
    • Anti-platelet therapy stroke risk reduction
      Anti-platelet therapy after a stroke or TIA reduces the risk of nonfatal ischemic strokes by 28% and fatal strokes by 16%.  
    • Aspirin as stroke prevention
      Aspirin reduces stroke rate by 20% in patients with myocardial infarction.  
    • Pioglitazone associated with relative risk reduction in recurrent stroke
      The PROactive trial to manage glucose in diabetics with a history of cardiovascular disease, stroke, or other vascular risk factors found that treatment with pioglitazone was associated with a 47% relative…  
    • Antihypertensive drugs used to reduce stroke recurrence
      Treatment of high blood pressure with antihypertensive drugs is associated with a significant reduction in risk of recurrent stroke.  
    • Lowering blood pressure associated with reduction in stroke risk
      Lowering of blood pressure is associated with a 30% to 40% reduction in stroke risk.  
    • Effectiveness of treating ischemic stroke victims with rt-PA within 3 hours of symptom onset
      A study of the effectiveness of treating ischemic stroke victims with rt-PA within 3 hours of symptom onset found an estimated impact on long-term health outcomes of 564 quality-adjusted life-years saved…  
    • Identifying individuals at high risk for developing AFib
      Using simple bedside measures, identification of individuals at risk for developing atrial fibrillation is feasible. Selecting high-risk individuals for inclusion in atrial fibrillation prevention trials may also enhance prevention strategies.  
    • Catheter ablation reduces risk of stroke and death among AFib patients
      Atrial fibrillation patients who underwent catheter ablation had a reduced risk of stroke and death—2.2% of those who had ablation experienced stroke versus 4.7% on medications alone, and 6% died from…  
    • Decrease in AFib hospitalization rates
      The use of practice guidelines in atrial fibrillation patients saw a decrease in rate of hospitalization from 74%to 38%.  
    • Stroke risk reduction from thrombin inhibitor in AFib patients
      A recently approved direct thrombin inhibitor was found to reduce the risk of stroke/peripheral embolic events in atrial fibrillation patients by 34%, and the risk of hemorrhagic stroke by 74%—compared…  
    • Adjusted-dose warfarin reduced stroke risk in AFib patients
      Meta-analysis of randomized trials found that adjusted-dose warfarin reduced stroke risk in atrial fibrillation patients by 60%. Antiplatelet agents reduced risk by 20%.  
    • Aspirin use in AFib patients
      Meta-analysis of a number of randomized controlled trials found that aspirin use in atrial fibrillation patients reduced stroke risk by an average 22%.  
    • Stroke rates among Afib patients
      In one year, 58,283 of the 1.265 million Medicare beneficiaries with atrial fibrillation that did not receive prophylaxis suffered a stroke. For those who did receive anti-coagulants, 38,468 suffered strokes.  
    • Atrial fibrillation ablation prevents recurrence of AFib
      Atrial fibrillation ablation, which involves using a catheter inserted into the heart to destroy electrical conduction tissue in or near the atria, prevents the recurrence of atrial fibrillation in up…  
    • Effectiveness of pacemaker/defibrillators to control AFib
      Widespread use of pacemaker/defibrillators to control atrial fibrillation could result in a 50% decrease in stroke.